Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been given a consensus recommendation of “Hold” by the twenty analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $164.50.

Several brokerages have recently weighed in on ALNY. Citigroup lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and increased their price objective for the company from $170.00 to $175.00 in a research report on Friday, February 12th. Cowen upped their price target on shares of Alnylam Pharmaceuticals from $154.00 to $197.00 and gave the company an “outperform” rating in a research note on Wednesday, January 13th. Needham & Company LLC upped their price target on shares of Alnylam Pharmaceuticals from $160.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, February 12th. Morgan Stanley upped their price target on shares of Alnylam Pharmaceuticals from $203.00 to $206.00 and gave the company an “overweight” rating in a research note on Friday, February 12th. Finally, HC Wainwright upped their price target on shares of Alnylam Pharmaceuticals from $225.00 to $235.00 and gave the company a “buy” rating in a research note on Friday, February 12th.

In related news, COO Yvonne Greenstreet sold 3,125 shares of the firm’s stock in a transaction that occurred on Tuesday, January 12th. The shares were sold at an average price of $161.00, for a total value of $503,125.00. Following the completion of the transaction, the chief operating officer now owns 7,945 shares in the company, valued at approximately $1,279,145. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Laurie Keating sold 14,941 shares of the firm’s stock in a transaction that occurred on Tuesday, January 12th. The shares were sold at an average price of $160.20, for a total transaction of $2,393,548.20. Following the completion of the transaction, the executive vice president now owns 2,234 shares of the company’s stock, valued at approximately $357,886.80. The disclosure for this sale can be found here. Company insiders own 3.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $38,000. Ellevest Inc. boosted its position in shares of Alnylam Pharmaceuticals by 24.1% during the 4th quarter. Ellevest Inc. now owns 695 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 135 shares in the last quarter. Signaturefd LLC increased its stake in shares of Alnylam Pharmaceuticals by 98.5% during the 4th quarter. Signaturefd LLC now owns 953 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 473 shares during the last quarter. MUFG Americas Holdings Corp increased its stake in shares of Alnylam Pharmaceuticals by 34.5% during the 4th quarter. MUFG Americas Holdings Corp now owns 974 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 250 shares during the last quarter. Finally, Pacer Advisors Inc. increased its stake in shares of Alnylam Pharmaceuticals by 22.0% during the 4th quarter. Pacer Advisors Inc. now owns 1,022 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 184 shares during the last quarter. Institutional investors and hedge funds own 92.35% of the company’s stock.

Shares of Alnylam Pharmaceuticals stock traded up $1.52 on Thursday, reaching $142.19. 8,323 shares of the company were exchanged, compared to its average volume of 698,316. Alnylam Pharmaceuticals has a one year low of $103.65 and a one year high of $178.41. The company has a 50-day moving average of $143.88 and a 200 day moving average of $141.81. The company has a market capitalization of $16.64 billion, a price-to-earnings ratio of -17.97 and a beta of 1.47.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, February 10th. The biopharmaceutical company reported ($2.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.76) by ($0.33). Alnylam Pharmaceuticals had a negative return on equity of 65.96% and a negative net margin of 222.19%. The firm had revenue of $163.56 million for the quarter, compared to the consensus estimate of $142.49 million. During the same period last year, the company posted ($2.47) earnings per share. Analysts anticipate that Alnylam Pharmaceuticals will post -7.32 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Further Reading: What is a blue-chip stock?

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.